# Resalis Therapeutics SRL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resalis-therapeutics

- Industry: Biotechnology
- Headquarters: Turin, Italy
- Website: www.resalistherapeutics.com
- Total disclosed funding: $22M
- Latest round: Series A (Jan 4, 2024)
- Investors on record: 4

## About

Based in Turin, Italy, and founded in 2021, Resalis Therapeutics SRL operates as a biotechnology company that develops RES-010, a non-coding RNA (ncRNA)-based therapeutic solution for metabolic illnesses. In October 2024, Resalis Therapeutics SRL raised an undisclosed amount of venture funding from Sanofi. As of March 2023, the company is led by its CEO, Alessandro Toniolo. Resalis Therapeutics SRL develops RES-010, an antisense oligonucleotide (ASO) and convenient treatment providing disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis, as well as targeting miR-22, a central player in regulating lipid metabolism and energy consumption. RES-010 provides a long-lasting therapeutic effect, alone or in combination with approved drugs. The company addresses two indications, obesity and fatty liver disease, with a high need for disease-modifying drugs that provide sustained clinical benefit. The company will use the October 2024 funding to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial.

## Funding rounds

- Series A, Jan 4, 2024, $11M — Sunstone Life Science Ventures, Claris Ventures
- Seed, Feb 22, 2023, $11M — Italian Angels for Growth, Club Degli Investitori, Claris Ventures

## Investors

- Italian Angels for Growth (https://capitalatlas.ai/funds/italian-angels-for-growth) — Seed
- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Seed
- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Seed, Series A
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series A